Hemostasis & Tissue Sealing Agents Market continues to grow with Ethicon LLC introducing SURGICEL powered absorbable hemostat that assists to combat disruptive bleeding on broad and oozing surfaces

 

Hemostasis & Tissue Sealing Agents

Hemostatic treatment is a process that involves the removal of excess hemostatic fluid from the valves in your legs and/or the valves themselves. For those with hemostatic varicose veins, which is what many people experience with hemostatic therapy, a hemostatic varicose vein dresser may help to reduce the swelling and pressure on the legs.

Increasing incidence of injuries caused by sports activities and road accidents is expected to drive growth of the global hemostasis & tissue sealing agents market. According to the Centers for Disease Control and Prevention (CDC), around 8.6 million sports and recreation-associated injuries are reported each year in the U.S. According to the same source, the injury rates are higher among males, with children aged 5-14 years. Moreover, according to the World Health Organization (WHO), every year around 20 and 50 million people suffer from non-fatal injuries with many people suffering from a disability. Such a high incidence of these injuries has increased the demand for tissue sealing agents. Hemostasis and tissue sealing agents offer several advantages such as reduced operating time, minimal incision, and reduced post-operative infection risks, and more. Hence, such factors are expected to drive growth of the global hemostasis & tissue sealing agents market. Furthermore, increasing number of surgeries and the advent of ready-to-use products is expected to propel growth of the global hemostasis & tissue sealing agents market in the near future.

Stringent regulatory scenario related to product approval coupled with high cost of tissue sealing agents is expected to hamper growth of the global hemostasis & tissue sealing agents market in the near future. Among regions, North America is expected to witness significant growth in the global hemostasis & tissue sealing agents market. This is owing to rising prevalence of cardiovascular diseases and diabetes in the region. According to the American Diabetes Association, in 2018, around 34.2 million people in the U.S. had diabetes. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to increased medical tourism and surgical procedures across emerging economies such as China and India.

Key players involved in the global hemostasis & tissue sealing agents market are Johnson & Johnson, Bioster and Nycomed, CryoLife, Baxter, Entegrion, B. Braun, Cohera Medical, Advanced Medical Solutions Group, and Omrix Biopharmaceuticals.

For instance, in January 2018, Ethicon LLC, a subsidiary of Johnson & Johnson, launched SURGICEL powered absorbable hemostat that assists to combat disruptive bleeding on broad and oozing surfaces.


Comments

Post a Comment

Popular posts from this blog

Increasing Consumption and Production of Fertilizers to Upsurge the Growth of the Agrochemicals Market

Image
  Agrochemical products are those chemicals that are used to increase the production of an agricultural environment. Agrochemical chemicals typically include pesticides, fertilizers, lime precursors, acidizing and alkalizing agents (all of which are designed to alter the normal pH level of the soil), lime stabilizers, and other nutrients that are required for plant growth. These chemicals are widely used by farmers and are crucial to the functioning of modern agriculture. The use of these chemicals presents a number of concerns both from the perspective of the environment and the human body. The increasing need for improving crop production due to the growing concern of food security and lack of arable land is fueling the growth of agrochemicals market . Growing advancement in technology is raising adoption of advanced and sustainable farming practices which is again propelling the growth of the market. The increasing population coupled with the growing usage of fertilizers around th
Read more

High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

Image
  Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers. Market Dynamics R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market . For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 canc
Read more

Increasing Prevalence of Muscular Dystrophy to Augment the Muscular Dystrophy Treatment Market Growth

Image
  Muscular dystrophy is a common disease that causes muscles to become weaker and unable to continue to develop properly. Because it often affects young children as well as adults, it can be difficult to detect. However, once symptoms are noticed, steps must be taken to prevent the disease. There are many treatment options available for muscular dystrophy. The severity of the disease will determine what type of treatment is best for your situation. Muscular dystrophy treatment involves breathing aids, therapy, surgery, or medication, which may help maintain function, but life span is often shortened. Market Dynamics: Increasing prevalence or incidence of muscular dystrophy, especially in the North America, is expected to propel the growth of the muscular dystrophy treatment market . For instance, one in 3,500 male babies born worldwide are affected with Duchenne muscular dystrophy (DMD), according to the National Organization for Rare Disorders. Moreover, in 2019, around 349 new ca
Read more